Brief: Simcere Pharmaceutical Says New Drug Application Of Anti-Sars-Cov-2 Accepted By NMPA
16/01/2023 09:01
Jan 16 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* NEW DRUG APPLICATION OF ANTI-SARS-COV-2 INNOVATIVE DRUG
XIANNUOXIN ACCEPTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Source text for Eikon: ID:
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660